Smith & Nephew Buys Nucryst Pharma Assets For Initial $21 Million
11 Novembre 2009 - 11:36AM
Dow Jones News
Smith & Nephew PLC (SN.LN) said Wednesday its advanced wound
management unit has signed a definitive agreement to buy most of
the assets of Nucryst Pharmaceuticals Corp. (NCS.T) for an initial
$21 million, to be adjusted at closing for working capital
changes.
MAIN FACTS:
-Smith & Nephew will acquire the manufacturing assets from
Nucryst's Fort Saskatchewan, Canada operations and the intellectual
property estate.
-Terms of acquisition are pending approval by Nucryst
shareholders and the transaction is anticipated to close before the
end of the year.
-By London Bureau, Dow Jones Newswires; Contact Ian Walker; +44 (0)20 7842 9296; ian.walker@dowjones.com
Nucryst (NASDAQ:NCST)
Graphique Historique de l'Action
De Juin 2024 à Juil 2024
Nucryst (NASDAQ:NCST)
Graphique Historique de l'Action
De Juil 2023 à Juil 2024
Real-Time news about Nucryst Pharmaceuticals - Common Shares (MM) (NASDAQ): 0 recent articles
Plus d'articles sur Nucryst Pharmaceuticals Corp.